These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 8139085)
1. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. Schaefer EJ; Lamon-Fava S; Jenner JL; McNamara JR; Ordovas JM; Davis CE; Abolafia JM; Lippel K; Levy RI JAMA; 1994 Apr; 271(13):999-1003. PubMed ID: 8139085 [TBL] [Abstract][Full Text] [Related]
2. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. Bostom AG; Cupples LA; Jenner JL; Ordovas JM; Seman LJ; Wilson PW; Schaefer EJ; Castelli WP JAMA; 1996 Aug; 276(7):544-8. PubMed ID: 8709403 [TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Gordon DJ; Knoke J; Probstfield JL; Superko R; Tyroler HA Circulation; 1986 Dec; 74(6):1217-25. PubMed ID: 3536151 [TBL] [Abstract][Full Text] [Related]
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA; 1984 Jan; 251(3):351-64. PubMed ID: 6361299 [TBL] [Abstract][Full Text] [Related]
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Seman LJ; DeLuca C; Jenner JL; Cupples LA; McNamara JR; Wilson PW; Castelli WP; Ordovas JM; Schaefer EJ Clin Chem; 1999 Jul; 45(7):1039-46. PubMed ID: 10388480 [TBL] [Abstract][Full Text] [Related]
7. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Joshi PH; Khokhar AA; Massaro JM; Lirette ST; Griswold ME; Martin SS; Blaha MJ; Kulkarni KR; Correa A; D'Agostino RB; Jones SR; Toth PP; J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130348 [TBL] [Abstract][Full Text] [Related]
8. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Rifkind BM Am J Cardiol; 1984 Aug; 54(5):30C-34C. PubMed ID: 6382999 [TBL] [Abstract][Full Text] [Related]
9. [Coronary heart disease and lipoprotein (a): relationship with other lipid cardiovascular risk factors]. Nogués X; Sentí M; Pedro-Botet J; Molina L; Serrat R; Pons S; Rubiés-Prat J Med Clin (Barc); 1992 Feb; 98(5):171-4. PubMed ID: 1532436 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Luc G; Bard JM; Arveiler D; Ferrieres J; Evans A; Amouyel P; Fruchart JC; Ducimetiere P; Atherosclerosis; 2002 Aug; 163(2):377-84. PubMed ID: 12052486 [TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Klausen IC; Sjøl A; Hansen PS; Gerdes LU; Møller L; Lemming L; Schroll M; Faergeman O Atherosclerosis; 1997 Jul; 132(1):77-84. PubMed ID: 9247362 [TBL] [Abstract][Full Text] [Related]
12. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN. J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296 [TBL] [Abstract][Full Text] [Related]
13. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146 [TBL] [Abstract][Full Text] [Related]
14. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Cantin B; Després JP; Lamarche B; Moorjani S; Lupien PJ; Bogaty P; Bergeron J; Dagenais GR Am J Cardiol; 2002 Mar; 89(6):662-6. PubMed ID: 11897206 [TBL] [Abstract][Full Text] [Related]
15. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. Burgess S; Ference BA; Staley JR; Freitag DF; Mason AM; Nielsen SF; Willeit P; Young R; Surendran P; Karthikeyan S; Bolton TR; Peters JE; Kamstrup PR; Tybjærg-Hansen A; Benn M; Langsted A; Schnohr P; Vedel-Krogh S; Kobylecki CJ; Ford I; Packard C; Trompet S; Jukema JW; Sattar N; Di Angelantonio E; Saleheen D; Howson JMM; Nordestgaard BG; Butterworth AS; Danesh J; JAMA Cardiol; 2018 Jul; 3(7):619-627. PubMed ID: 29926099 [TBL] [Abstract][Full Text] [Related]
16. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA; 1984 Jan; 251(3):365-74. PubMed ID: 6361300 [TBL] [Abstract][Full Text] [Related]
18. Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia. Maciejko JJ; Brazg R; Shah A; Patil S; Rubenfire M Arch Fam Med; 1994 Nov; 3(11):955-60. PubMed ID: 7804477 [TBL] [Abstract][Full Text] [Related]